Briquilimab (JSP191)
Conditioning for HSCT in Severe Combined Immunodeficiency (SCID)
Key Facts
About Jasper Therapeutics
Jasper Therapeutics is on a mission to redefine conditioning for stem cell transplants and gene therapies by replacing toxic chemotherapy with targeted antibody-based regimens. Its core achievement is the development of briquilimab, a first-in-class anti-c-Kit antibody, which has demonstrated proof-of-concept in clinical trials for multiple indications. The company's strategy focuses on advancing briquilimab through key registrational studies in Severe Combined Immunodeficiency (SCID) and leveraging its platform to enable next-generation gene therapies, positioning itself at the intersection of transplant medicine and genetic medicine.
View full company profileAbout Jasper Therapeutics
Jasper Therapeutics is on a mission to redefine conditioning for stem cell transplants and gene therapies by replacing toxic chemotherapy with targeted antibody-based regimens. Its core achievement is the development of briquilimab, a first-in-class anti-c-Kit antibody, which has demonstrated proof-of-concept in clinical trials for multiple indications. The company's strategy focuses on advancing briquilimab through key registrational studies in Severe Combined Immunodeficiency (SCID) and leveraging its platform to enable next-generation gene therapies, positioning itself at the intersection of transplant medicine and genetic medicine.
View full company profileAbout Jasper Therapeutics
Jasper Therapeutics is on a mission to redefine conditioning for stem cell transplants and gene therapies by replacing toxic chemotherapy with targeted antibody-based regimens. Its core achievement is the development of briquilimab, a first-in-class anti-c-Kit antibody, which has demonstrated proof-of-concept in clinical trials for multiple indications. The company's strategy focuses on advancing briquilimab through key registrational studies in Severe Combined Immunodeficiency (SCID) and leveraging its platform to enable next-generation gene therapies, positioning itself at the intersection of transplant medicine and genetic medicine.
View full company profileAbout Jasper Therapeutics
Jasper Therapeutics is on a mission to redefine conditioning for stem cell transplants and gene therapies by replacing toxic chemotherapy with targeted antibody-based regimens. Its core achievement is the development of briquilimab, a first-in-class anti-c-Kit antibody, which has demonstrated proof-of-concept in clinical trials for multiple indications. The company's strategy focuses on advancing briquilimab through key registrational studies in Severe Combined Immunodeficiency (SCID) and leveraging its platform to enable next-generation gene therapies, positioning itself at the intersection of transplant medicine and genetic medicine.
View full company profileAbout Jasper Therapeutics
Jasper Therapeutics is on a mission to redefine conditioning for stem cell transplants and gene therapies by replacing toxic chemotherapy with targeted antibody-based regimens. Its core achievement is the development of briquilimab, a first-in-class anti-c-Kit antibody, which has demonstrated proof-of-concept in clinical trials for multiple indications. The company's strategy focuses on advancing briquilimab through key registrational studies in Severe Combined Immunodeficiency (SCID) and leveraging its platform to enable next-generation gene therapies, positioning itself at the intersection of transplant medicine and genetic medicine.
View full company profile